Apimeds Pharmaceuticals US
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell APUS and other ETFs, options, and stocks.About APUS
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. It primarily focuses on developing innovative therapies for inflammation and pain management in knee osteoarthritis (OA) and, to a lesser extent, multiple sclerosis (MS).
CEOVinod Menon
CEOVinod Menon
Employees2
Employees2
HeadquartersMatawan, New Jersey
HeadquartersMatawan, New Jersey
Founded2020
Founded2020
Employees2
Employees2
APUS Key Statistics
Market cap27.29M
Market cap27.29M
Price-Earnings ratio-5.06
Price-Earnings ratio-5.06
Dividend yield—
Dividend yield—
Average volume212.79K
Average volume212.79K
High today$3.00
High today$3.00
Low today$1.96
Low today$1.96
Open price$2.08
Open price$2.08
Volume1.23M
Volume1.23M
52 Week high$4.03
52 Week high$4.03
52 Week low$1.37
52 Week low$1.37
Stock Snapshot
Apimeds Pharmaceuticals US(APUS) stock is priced at $2.25, giving the company a market capitalization of 27.29M. It carries a P/E multiple of -5.06.
As of 2026-01-24, Apimeds Pharmaceuticals US(APUS) stock has fluctuated between $1.96 and $3.00. The current price stands at $2.25, placing the stock +14.7% above today's low and -25.0% off the high.
The Apimeds Pharmaceuticals US(APUS)'s current trading volume is 1.23M, compared to an average daily volume of 212.79K.
In the last year, Apimeds Pharmaceuticals US(APUS) shares hit a 52-week high of $4.03 and a 52-week low of $1.37.
In the last year, Apimeds Pharmaceuticals US(APUS) shares hit a 52-week high of $4.03 and a 52-week low of $1.37.
People also own
Based on the portfolios of people who own APUS. This list is generated using Robinhood data, and it’s not a recommendation.